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Summary
Iron deficiency is frequent among athletes. All types of iron
deficiency may affect physical performance and should be
treated. The main mechanisms by which sport leads to iron
deficiency are increased iron demand, elevated iron loss
and blockage of iron absorption due to hepcidin bursts.
As a baseline set of blood tests, haemoglobin, haematocrit,
mean cellular volume, mean cellular haemoglobin and ser-
um ferritin levels help monitor iron deficiency. In healthy
male and female athletes >15 years, ferritin values <15 mcg
are equivalent to empty, values from 15 to 30 mcg/l to low
iron stores. Therefore a cut-off of 30 mcg/l is appropriate.
For children aged from 6–12 years and younger adoles-
cents from 12–15 years, cut-offs of 15 and 20 mcg/l, re-
spectively, are recommended. As an exception in adult elite
sports, a ferritin value of 50 mcg/l should be attained in
athletes prior to altitude training, as iron demands in these
situations are increased.
Treatment of iron deficiency consists of nutritional coun-
selling, oral iron supplementation or, in specific cases, by
intravenous injection. Athletes with repeatedly low ferritin
values benefit from intermittent oral substitution. It is im-
portant to follow up the athletes on an individual basis, re-
peating the baseline blood tests listed above twice a year. A
long-term daily oral iron intake or i.v. supplementation in
the presence of normal or even high ferritin values does not
make sense and may be harmful.
Key words: iron deficiency in sports; iron deficiency and
performance; diagnosis of iron deficiency; ferritin cut-off;
dilutional pseudoanaemia in sports; treatment of iron
deficiency
Introduction
Iron deficiency among athletes, in males and more often
in females, is a commonly encountered condition for the
sports medicine physician. Iron deficiency is one of the
most common deficits globally with a clear predominance
in adolescence and in menstruating females [1]. Data from
a general Swiss population show frequencies for iron de-
ficiency for menstruating females of 22.7%, for male mil-
itary recruits of 7.2% and for iron deficiency anaemia of
2.2% (females) and 0.1% (males) [2, 3]. In sports the rate
of iron deficiency is distinctly higher, up to 52% in female
adolescent athletes, and occurs more often in endurance
sports and in disciplines with a high prevalence of eating
disorders [4–6]. These abnormal findings need a careful
clinical look as iron deficiency affects many organ systems
of the body and not just oxygen transport, especially in
sports [7].
On the other hand, Switzerland has recently experienced
some kind of “iron hype” for various reasons. Not all of
them seem to be rational [8, 9]. The problem is enhanced
by the finding of an earlier study among Swiss top athletes,
showing that iron supplements were consumed to some ex-
tent uncritically and in excess [10, 11].
Sports medicine physicians are often in charge of male and
female athletes at their peak performance. In this role, they
are aware of the importance of adequately diagnosing and
treating iron deficiency in all its aspects, but at the same
time to prevent iron overload. This article is a consensus
statement of the Swiss Society of Sports Medicine and
provides an overview and practical guidelines for the dia-
gnosis and treatment of iron deficiency in sports and should
help clinicians in decision making.
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Definition of iron deficiency and
general function of iron
Iron is a transition metal and has multiple functions in
more than 180 biochemical reactions in the human body in-
cluding electron transport in redox reactions (cytochromes,
sulphuric proteins), redox catalytic functions (cytochrome
p450, catalase, peroxidase) and reversible storage and
transport of O2 (haemoglobin, myoglobin). It also plays an
important role in the production of neurotransmitters, and
is essential in synaptogenesis and myelinisation. Moreover
oxidative phosphorylation is the most critical biochemical
pathway in which iron is involved [8, 12].
Figure 1 gives an overview of iron distribution in the hu-
man body. The total body content of iron amounts to ap-
proximately 4 g in men and 2.5 g in women. This iron is
divided up between three active sites, firstly haemoglobin,
myoglobin and enzymes. The rest (20% of total) remains
as inactive, depot iron in the form of ferritin and haemos-
iderin. Finally, 0.2% of the total iron exists as transport
iron in the form of transferrin. In adolescents the relative
amount of iron in the different compartments is comparable
but may vary slightly depending on body size and initiation
of menses (fig. 1) [8].
The usual loss of iron (1 mg per day in males and 2 mg
per day in females) due to gastrointestinal epithelial shed-
ding and menstruation is compensated by absorption in the
small intestine [13, 14]. Of the ingested iron of 10–14 mg,
the enterocytes absorb only about 0.5–2 mg (5–15%) [14,
Figure 1
Iron compartments.
Figure 2
Hepcidin effects, adapted after Young and Zaritsky. Republished
with permission of Americal Society of Nephrology, from Young B,
Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol.
2009;4:1384–7; permission conveyed through Copyright Clearance
Center, Inc.
15]. Nevertheless, during increased losses (e.g. microis-
chaemia in sports, bleeding, haemolysis) and elevated de-
mand (e.g. growth with the building up of the adult haemo-
globin mass, pregnancy), adequate uptake is guaranteed
through an up to four-fold elevated intestinal absorption
as long as sufficient iron is provided by nutritional intake
[14].
The absorbed iron is stored in ferritin in the cytoplasm of
the enterocytes [12]. To export the iron to the plasma, the
iron is carried out by ferroportin on the basolateral surface
of the enterocytes. There, iron is bound to transferrin and
transported to the liver where it is stored as ferritin or trans-
ferred to the iron consuming tissues e.g. bone marrow.
Ferroportin is important in the tight regulation of iron
homeostasis. The main regulatory constituent is hepcidin
[16]. Synthesised in hepatocytes, hepcidin regulates iron
export out of the storing cells. In phases of high iron load-
ing and in response to inflammatory processes the synthes-
is of hepcidin is increased, leading to the internalisation of
ferroportin on enterocytes, which in turn blocks iron trans-
portation into the circulation. The same mechanism leads
to a blockade of iron within the macrophage system, thus
preventing the transfer of iron from macrophages to eryth-
roblasts, the precursors of erythrocytes [12] (fig. 2).
Any type of exercise will also cause some kind of in-
flammation in the body, as this inflammation and the sub-
sequent repair mechanisms are the basis of adaptation to
training. The size of the inflammatory response depends
on the type, intensity and duration of the training. Several
markers of iron metabolism are affected by the inflammat-
ory cascade, as they are part of the acute-phase response
[18]. Concerning iron metabolism, intensive training has
been shown to lead to distinct increases in hepcidin [5, 19,
20]. This leads to a block of iron absorption, disruption of
iron transfer from macrophages to erythroblasts and may
possibly induce iron deficiency. Hepcidin synthesis is, on
the other hand, suppressed by erythropoetic activity and an-
aemia. This allows increased intestinal absorption and util-
isation of iron from the macrophages and hepatocytes un-
der conditions of elevated iron loss or increased demand
[21, 22].
Up to now the main mechanism by which sport causes an
increase of iron loss was explained by microischaemia of
the gut during excessive training [23, 24]. Losses through
excessive sweating [25] and possible blood loss in the urin-
ary tract [26] are in absolute terms not relevant. Foot-strike
haemolysis, which describes the mechanical destruction of
red blood cells in the foot of the running athlete does exist
[27, 28], but as the salvage of blood constituents is com-
plete there is no loss of iron. Newer results show that there
is the additional mechanism explained above where parti-
cipation in intensive sport triggers hepcidin bursts, causing
blockage of iron [20].
Figure 3 describes the different stages of progressive iron
deficiency: When iron losses exceed absorption or absorp-
tion falls below demand, initially iron stores will deplete,
resulting in a reduced ferritin level. At a certain point,
the stored iron is too low to provide the tissues with suf-
ficient iron. This will induce the production of zinc-pro-
toporphyrin (ZnPP) and an increase of soluble transferrin
receptor (sTfR). As haemoglobin, mean cellular volume
Review article Swiss Med Wkly. 2015;145:w14196
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(MCV), and mean cellular haemoglobin (MCH) are still
normal, this condition is called nonanaemic iron deficiency
(NAID). NAID is defined as a deficiency of iron without
affecting haematopoiesis.
If iron balance remains negative, the youngest red cells will
be insufficiently haemoglobinised and thus appear as hypo-
chromic and microcytic, with lower MCH and MCV than
the entire cell population. If progression of iron deficiency
continues, MCH and MCV will drop below the lower limit
of the normal range (28 pg and 80 fl, respectively) and iron
deficiency with microcytosis and/or hypochromia (IDMH)
develops. IDMH is defined as an iron deficiency affecting
haematopoiesis. In this case, ferritin is <30 mcg/l, the red
cell indices are mostly, but not always, affected and the
concentration of haemoglobin is still normal (men >140 g/l,
women >120 g/l) [29].
Ultimately, haemoglobin concentrations will drop below
the lower limit of the normal range and frank iron deficient
anaemia (IDA) is established [29]. In IDA ferritin and
haemoglobin are lowered and the red cell indices are re-
duced or normal [29].
A further particular situation is the functional iron defi-
ciency encountered in patients with anaemia of chronic dis-
order, or tumour or haemodialysis patients. The iron de-
mand is higher than the iron supply out of the iron stores. In
consequence hypochromic reticulocytes and erythrocytes
are formed, the haemoglobin in reticulocytes (CHr or Ret-
He, table 1) falls <28 pg [30, 31]. This situation is a result
of elevated interleukin-6 and hepcidin levels seriously im-
pairing iron turnover and may therefore occur with normal
or even elevated ferritin values, reflecting normal iron
stores [21, 31].
The basic measurements are shown in figure 4: these are
haemoglobin, haematocrit, and erythrocyte count, with cal-
culation or measurement of the red cell indices MCV and
MCH. Table 1 gives an overview and explains cut off val-
ues of relevant tests to diagnose NAID, IDMH and IDA.
Ferritin is the most widely used parameter in the evaluation
of iron deficiency. Since ferritin also acts as an acute phase
protein each inflammatory process should be excluded by
the patient history. Additionally, it should be considered
that even heavy/powerful sporting activities might increase
acute phase reactants [37, 40–42]. Depending on duration
and intensity of the activity, ferritin values may stay nor-
mal, show a rise of 27% [40] with a return to baseline with-
in a day or, in the case of ultramarathons, be double as high
as the prerace value and return to baseline only after 6 days
[42, 43].
Free serum iron has a high daytime and high variability
between one person and another. Morning values are at a
peak more than twice as high as values measured 12 hours
later, so it cannot be used to represent iron in the body.
Furthermore, free serum iron is lowered with acute phase
reactions and elevated in cases of haemolysis after blood
sampling. Nowadays it is an obsolete marker and should
be used only to calculate transferrin saturation or in situ-
ations of acute iron intoxication [29]. Transferrin saturation
has some benefit for classification of iron deficiency. A cut
off of 20% and below is accepted as definition of iron defi-
ciency [29]. As free serum iron is needed for its calculation,
one must be aware of this limitation, particularly in inflam-
mation where transferrin saturation may be between 10 and
20% without iron deficiency.
The indirect markers ZnPP [38, 39] and sTfR [29, 37]
may be additionally useful to define IDMH and differenti-
ate NAID from a functional iron deficiency. The sTfR was
thought to be an excellent parameter because it is not in-
fluenced by inflammation and exercise. But it is mostly el-
evated during increased erythropoesis, so it may be of only
additional value. ZnPP is reentering routine testing now
and gives additional information to judge the iron status of
erythropoesis.
Hepcidin has been established as a key regulator of iron ab-
sorption from the enterocytes and release from the macro-
phages; however, it has not yet entered routine testing [16,
21].
Iron deficiency in sports – influence
on performance
Dilutional pseudoanaemia
Anaemia is defined by a lowered haemoglobin concentra-
tion in a venous blood sample. This definition neglects the
Figure 3
Stages of iron deficiency.
Hb = haemoglobin; IDA = iron deficiency anaemia; IDMH = iron
deficiency with microcytosis and/or hypochromia; MCH = mean
cellular haemoglobin; MCV = mean cellular volume; NAID =
nonanaemic iron deficiency; sTfr = soluble transferrin receptor;
ZnPP = zinc protoporphyrin
Figure 4
Overview of diagnosis and indications for treatment in adults.
CRP = C-reactive protein; Hb = haemoglobin; Hk = haematocrit;IDA
= iron deficiency with anaemia; IDMH =iron deficiency with
microcytosis and/or hypochromia; MCH = mean cellular
haemoglobin; MCV = mean cellular volume; NAID = nonanaemic
iron deficiency; ; ZnPP = zinc protoporphyrin
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fact that anaemia is the real reduction of the total haemo-
globin mass in the body, a so-called absolute anaemia (see
fig. 4). In contrast, relative or dilutional pseudoanaemia
Figure 5
Total blood volume of male and female untrained, top athletes and
athletes with dilutional pseudoanaemia in ml [44, 46, 49].
APA = athlete with dilutional pseudoanaemia; TA = top athlete; UT
= untrained
In the column of the red cell mass the haematocrit in percentage is
shown in white letters.
is defined as a lowered haemoglobin and haematocrit ow-
ing to a distinctly elevated plasma volume with normal red
cell mass and total haemoglobin mass. The other blood
parameters, particularly ferritin, MCV and MCH are within
the normal range and performance is not affected. This
plasma volume increase is considerable and is due to re-
peated bouts of physical training over the years. It mag-
nitude depends on the intensity and duration of the effort.
In about 10–15% of mainly endurance athletes, especially
when training time exceeds 10 hours per week, this dilu-
tional pseudoanaemia can be observed [44]. The same di-
lutional effect is found in ultralong endurance disciplines
or sports events lasting several days (e.g. road cycling
tours). As seen in figure 5, in male and female athletes with
dilutional pseudoanaemia the increase in plasma volume
causes a slight lowering of the haematocrit while the red
cell mass stays high [42, 45–48].
This is why top level endurance athletes show a high cor-
relation between haemoglobin mass and endurance capa-
city, but a low correlation between haematocrit or haemo-
globin concentration and endurance capacity [49, 50].
Table 1: Relevant tests to define anemia, NAID, IDMH and IDA.
Parameter Cut-off Comment/Cave
Hb Women: >120 g/l
Men: >140 g/l
Defines diagnosis of anaemia
MCH >28 pg Categorises anaemia
MCV >80 fl Categorises anaemia (as a result of a certain instability after blood sampling, less useful than MCH)
%HYPO
Percentage of
hypochromic
erythrocytes
[32, 33]
%HYPO <10 Indicates iron deficiency and its influence on haematopoiesis at an earlier stage, particularly IDMH. Iron deficiency,
affecting erythropoiesis, is followed by an increase in %HYPO within 1–2 weeks. In patients with a low ferritin, means
empty iron stores, a normal %HYPO would indicate that the erythropoiesis is not yet affected.
Limitation: availability of the method
Reticulocyte
count, absolute
20–100 (×109/l)
Reference values of the
manufacturer need to be
respected.
Assesses red blood cell production
Reticulocyte
indices [30, 31,
34, 35]
MCVr, 92–120 fl
Mean cellular volume of
reticulocytes in fl CHr 28–35 pg
[31]
Amount of Hb in reticulocytes
(measured in Advia 120) Ret-He
28–35 pg [36]
Amount of Hb in reticulocytes
(measured in Sysmex NE 2100)
A lowering of the MCVr and even more specificly the CHr and Ret-He are very early indicators of the iron demand of
erythropoiesis. CHr or Ret-He react quickly within 48–72 h to an increased demand or lowered supply, compared with,
e.g., MCV and MCH which react only within weeks.
Limitation: availability of the method
Ferritin 30 mcg/l The most widely used parameter for IDA.
Limitations: as an acute phase protein, ferritin is increased during inflammation and infection, after intensive exercise,
in pregnancy and with liver damage, see also CRP
CRP <3 mg/l Acute phase protein, indicating infection and inflammation
Transferrin
saturation
>20% <20% indicates an iron deficiency
Limitations: acute phase reactions lower the transferrin saturation without iron deficiency. Moreover, as free serum iron
is used for the calculation, transferrin saturation may also vary.
sTfR Reference values of the
manufacturer need to be
respected, as they differ
substantially!
Woman: 0.75–1.5 mg/l
Men: 0.75–1.75 mg/l
Indirect marker to define IDMH and NAID. Similar sensitivity as ZnPP for NAID and IDMH. Not influenced by
inflammation and exercise [ 37]
ZnPP [38, 39] <50 mcmol/mol Hb excludes iron
deficient erythropoiesis,
>100 mcmol/mol Hb indicates
iron deficient erythropoiesis
Indirect marker to define IDMH and NAID. Early marker of NAID and increases to higher values in IDMH [29].
Not as much influenced by inflammation as ferritin
Hepcidin Not entered routine laboratory
testing yet
Key regulator of iron absorption from erythrocytes [21]
Elevation impairs haematopoiesis [14, 22]
CRP = C-reactive protein; Hb = haemoglobin; IDA =iron deficiency with anaemia; IDMH = iron deficiency with microcytosis and/or hypochromia; MCH = mean cellular
haemoglobin; MCV = mean cellular volume; NAID = nonanaemic iron deficiency; sTfR = solublle transferrin receptor; ZnPP = zinc protoporphyrin
Review article Swiss Med Wkly. 2015;145:w14196
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 4 of 15
Therefore, the haemoglobin mass is the important factor
for endurance capacity, while having a high plasma volume
accompanied by a low haematocrit is by no means a dis-
advantage [51–53]. A larger intravascular volume has be-
Table 2: Randomised blinded interventional trials investigating NAID and performance.
First author Performance
measurement
n / Study population Inclusion criteria Intervention Results
Burden 2014
[63]
VO2 max
Time to exhaustion
Running economy
Haemoglobin mass
15
Runners
9 F, VO2 max 64.5 ml/
kg·min
6 M VO2 max 76.7 ml/
kgmin
Females:
Hb >120 g/l Fer <30
mcg/l
Males:
Hb >120 g/l Fer <40
mcg/l
i.v. 500 mg Fe-
carboxymaltose vs
placebo
Testing at BL, after 7
days and after 4 wk
Blood sampling as
above and one day
after injection
– Fer ↑, traSat ↑, serum iron ↑ in Tx, Fer → in P
– Hepcidin ↑ from day 1 up to four weeks in Tx
– Hb mass →, VO2 max →, running economy →,
time to exhaustion → in Tx and P
Garvican 2014
[64]
Treadmill running with
VO2 max, time to
exhaustion
Haemoglobin mass
27
Highly trained distance
runners
13 M, 14 F
4 randomised
treatments: LG oral, LG
i.v., CG oral, CG i.v.
Low group (LG)
Fer <35 mcg/l and trSat
<20% or Fer <15 mcg/l
Control group (CG)
Fer <65 mcg/l
Oral: 105 g elemental
iron 2×/d in LG; 1×/d in
CG
i.v.: 2–4 injections Fe-
carboxymaltose due to
iron status (mean i.v.
CG 375 – mean i.v. LG
550 mg)
BL testing and after 6
wk
– Fer ↑ with oral and i.v. treatment, but
significantly ↑ with i.v.
– Hb → in all groups
– In LG i.v.: Hb mass ↑, VO2 max ↑ and time to
exhaustion ↑
Authors named CG SUB group, having a
suboptimal iron status. But there was no change
in Hb mass, VO2 max and time to exhaustion in
this group.
Della-Valle
2014 [65]
4 km time trial
VO2 peak
40
Female rowers
At the beginning of a
season!
Hb >120 g/l
Fer <20 mcg/l
Oral 100 mg FeSO4/d
vs placebo for 6 wk
Testing at BL and after
6 wk of training
– Fat free mass ↑ and VO2 peak ↑ in Tx and P
– Fer ↑ in Tx
– Lower lactate response during first half of time
trial and after 5 min recovery in Tx
– Energy expenditure in Tx ↑, lactate response ↓
in first half of time trial in Tx, and 5 min after time
trial↓
Waldvogel
2012 [66]
Chester step test (r =
0.92 to VO2 max)
Fatigue (VAS 10)
154
Female blood donors
Hb >120 g/l
Fer ≤30 mcg/l
Oral 80 mg FeSO4/d vs
placebo for 4 wk
BL (1 wk after donation
of 450 ml blood) and
after 4 wk.
In Tx Hb ↑, Fer ↑ compared with P
No significant effect for fatigue, aerobic capacity (
step test), mood disorder, quality of life
McClung 2009
[67]
2 mile running time
Profile of mood state
219
Female soldiers during
basic combat training
Three groups:
IDA (P 17 / Tx 18)
ID (P 14 / Tx 14)
Normal (P 51 / Tx 52)
No inclusion criteria.
IDA defined as:
Hb <120 g/l
and ≥2 of:
Fer <12 mcg/l, traSat
<16%, RDW >15%
ID defined as ≥2 of iron
crit.
Oral 100 mg FeSO4/d
vs placebo
Testing at BL and after
8 wk of basic combat
training
– RDW ↑, sTfr↑, Fer↓ in Tx and P.
– Decrement in iron status ↓ in Tx
– In soldiers with IDA and Tx
– 2 mile running time↓ but not in P and Normal,
– POMS↑ in Tx, P and Normal, but only in IDA
vigour scores of POMS↑
Hinton 2007
[68]
VO2 max
60 min submax. cycle
ergometer test (at 60%
VO2 max)
20
Recreationally trained
(3 M, 17 F)
Hb >120 g/l F
Hb >130 g/l M,
Fer <16 mcg/l, sTfr >8
mg/l, or sTfr / log Fer
index >4.5
Oral 30 mg elemental
iron as FeSO4/d vs
placebo
Testing at BL and after
6 wk
– Fer↑ in Tx, Hb and haematocrit →
– In P ventilatory threshold↓, in Tx ventilatory
threshold→
– Energetic efficiency during submaximal tes ↑ in
Tx
Brownlie 2004
[69]
15 km time trial on cycle
ergometer
VO2 max
41
Untrained women
Training of 30 min/d,
5×/wk for the final 4 wk
Hb >120 g/dl,
Fer <16 mcg/l
Oral 100 mg FeSO4/d
vs placebo
Testing at BL and after
6 wk
Time in time trial↓, percentage of VO2 max ↓ ,
work rate ↓ in Tx when sTfr >8 mg/l
No difference with normal sTfr
Brownlie 2002
[70]
VO2 max 41
Untrained women
Training of 30 min/d,
5×/wk for the final 4wk
Hb >120 g/dl,
Fer <16 mcg/l
Oral 50 mg FeSO4/d vs
placebo for 6wk
Testing at BL and after
6 wk
– Fer ↑, traSat ↑ in Tx
– VO2 max ↑in Tx and P, but VO2 max was
significantly higher in Txr
Friedman 2001
[71]
Treadmill VO2 max
Anaerobic capacity (O2
consumption)
Haemoglobin mass
40
Young elite athletes
Hb >135 g/l M,
Hb >117 g/l F
Fer <20 mcg/l
Oral 200 mg elemental
iron/d vs placebo for 12
wk
Testing at BL and after
12 wk
– Fer ↑ in Tx, whereas P →
Venous Hb and Hb mass → in Tx and P
VO2 max ↑ and O2 consumption ↑ inTx
Hinton 2000
[72]
15 km time trial on cycle
ergometer
42
Women
Training of 30 min/d,
5×/wk for the final 4 wk
Hb >120 g/l
Fer <16 mcg/l
Oral 100 mg FeSO4/d
vs placebo for 6 wk
Testing at BL and after
6 wk
– Fer ↑ and Hb ↑ in Tx
– 15 km time ↓ in Tx and P, but significantly ↓ in
Tx (p = 0.04)
↑ = increased significantly; → = no change; ↓ = lowered significantly; BL = baseline; CG = control group; F = female; Fer = ferritin; Hb = haemoglobin; ID = iron deficiency;
IDA = iron deficiency anaemia; LG = low group; M = male; NAID = nonanaemic iron deficiency; P = placebo group; POMS = profile of mood state; RDW = red cell
distribution width; SUB = group with suboptimal iron status; traSat = transferrin saturation; Tx = treatment group; VAS = visual analogue scale
Review article Swiss Med Wkly. 2015;145:w14196
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neficial effects on performance, as it improves thermoreg-
ulation, increases cardiac preload and enhances the body´s
ability to dilute metabolites. The exact mechanism for this
adaptation remains to be explored, and shifts in proteins
and electrolytes are thought to play a role [54]. Exercise in-
duced plasma volume shifts are usually reversible within
days after cessation of the physical effort [40].
A dilutional pseudoanaemia cannot be ruled out by a ven-
ous blood examination only, but in clinical practice serial
measurements of the basic blood examination are helpful.
These include measurements during the training pause at
the end of the season (haematocrit, Hk↑), during the season
(Hk↓), once immediately after an intensive and long lasting
training session (Hk↑) and 24–48 h after this session (Hk↓).
If these serial measurements do not reveal the expected
variations of the haematocrit (showing at least normal val-
ues in the training pause at season’s end) the measurement
of haemoglobin mass to confirm the dilutional pseudoan-
aemia may be considered with, for example, the CO
rebreathing method [48–50].
Excessive haematocrits
Unfortunately, top level road cyclists 15 years ago often
showed excessive haematocrit levels of over 50%, excep-
tionally up to 60%. Based on the confessions of several
riders, these values could only be reached by mostly sys-
tematic doping procedures with mainly erythropoietin,
growth hormone and testosterone. During longer lasting
competitions blood transfusions (retransfusion of own
blood, collected several months before) [55] were given
to boost oxygen carrying capacity. Through awareness of
these doping procedures, health control tests with blood
sampling were introduced, with upper limits of the
haematocrit (e.g. the 50% rule of the Union de Cyclisme
International [56]) or haemoglobin concentration (e.g. 170
g/l for males, 160 g/l for females of the Fédération Inter-
national de Ski [57]) to protect athletes from fatal throm-
botic events. These were followed by newer doping tests
(e.g. EPO-tests, growth hormone) and antidoping strategies
such as the biological passport [58]. Several blood samples
collected over the year provide an individual blood profile
and allow individual reference values to be established for
each athlete [59]. This biological passport proposed by the
WADA (World antidoping agency) gives a much closer
follow-up and is used in cases of violation of the antidop-
ing code [58].
Influence of iron on physical performance
Iron is, in addition to its function in oxygen transport, a
key component of the enzymatic system of the respiratory
chain. These presumably distinct roles were investigated in
early animal studies [60–62]. In these studies, the authors
aimed at differentiating between a decline in performance
due to anaemia and a decline due to enzymatic impairment.
Using an animal model in a cross-over setting with iron de-
pletion and cross-over transfusion to correct for anaemia,
it was shown that not only anaemia but also iron depletion
without anaemia led to a significantly decreased number
of mitochondria and reduced activity of the respiratory en-
zymes. The authors therefore postulated that iron depletion
without anaemia affected oxidative capacity, whereas an-
aemia affected mostly oxygen transport [60–62].
At present the cut-off for ferritin is still debated with values
ranging from 15 mcg/l from the World Health Organization
[73] to 16–32 mcg/l [74, 75] in studies that used the “gold
standard procedure of bone marrow staining”. It has to be
noted that studies investigating this matter were not all con-
clusive and some presented controversial results [76, 77].
If not only erythropoiesis but also clinical symptoms of an
iron deficiency such as fatigue (but not yet performance)
are considered, the cut-off may be slightly higher. Recently
Krayenbuehl et al. showed in their double-blind random-
ised study with intravenous iron administration in nonan-
aemic premenopausal women with low ferritin and fatigue
an improvement in mood state in the ferritin group <15
mcg/l [78]. Earlier, Verdon et al. analysed fatigue and mood
state with oral therapy in a family doctor’s office setting.
They found that nonanaemic women with ferritin concen-
trations below 50 mcg/l improved with oral supplementa-
tion [79]. Vaucher et al came to comparable results [80].
But their proposed cut-off of 50 mcg/l must be interpreted
with caution because of methodological concerns (e.g. as-
sessment of stool coloration by iron not blinded, definition
of iron deficiency based on a limited number of variables).
A few studies have integrated a performance measure
(table 2). McClung et al showed in female military recruits
treated with oral iron or placebo an improvement in run-
ning performance in recruits with IDA. Those with NAID
showed an improved mood state, but no change in per-
formance. Since then, several other studies have shown a
performance impairment in nonanaemic iron-depleted en-
durance athletes [68–70, 72, 81]. A limiting factor of all
these studies is the influence of training or mild changes in
haematological parameters of other origin, both of which
are difficult to quantify. Garvican et al very recently per-
formed a study with 27 highly trained distance runners (13
male and 14 female athletes) with measurement of haemo-
globin mass and endurance performance. They compared
in a randomised controlled setting intravenous iron versus
6 weeks of oral treatment with one group having clearly de-
ficient iron stores (ferritin <15 mcg/l or ferritin <35 mcg/l
and transferrin saturation <20%) and the other with better
iron stores but a ferritin level of <65 mcg/l. Both forms of
supplementation substantially increased ferritin levels, but
haemoglobin concentration did not change in any group.
Haemoglobin mass increased in the iron deficiency group
with intravenous treatment accompanied by an increase in
VO2 max and run time to exhaustion, whereas the group
with ferritin <65 mcg/l did not show any changes in these
parameters [53, 64].
As multiple muscle enzymes are affected other functions
related to performance have been investigated. Brutsaert et
al. found an increase in knee extensor strength after iron
supplementation in nonanaemic iron-depleted volunteers
using a randomised controlled study design, which points
towards a role of iron in resistance to fatigue and adaptation
to training [82]. Very recently Della Valle et al investigated
female rowers with NAID under oral iron supplementation
for 6 weeks in a double-blind design. They were able to
show an improvement of iron status and a better energetic
efficiency in the iron group [65].
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Based on the cited results and according to several review
articles, a ferritin cut-off of 30 mcg/l in adults seems to be
most plausible [8, 83–90].
Iron deficiency in sports – therapy
Nutrition
The first step in therapy of iron deficiency is the correction
of the nutritional iron intake. In nutrition, haem iron
(mainly in meat) and free iron as Fe2+ or Fe3+ exist. Oral
uptake studies show that the uptake of haem iron is much
better than the uptake of free iron [91]. For the latter, up-
take of Fe2+ is better than uptake of Fe3+ [92]. Meat, liv-
er, poultry or fish contain haem iron as well as free iron. A
vegetarian diet contains only free iron. The bioavailability
of iron is very variable and depends much on actual iron
stores [93], ranging from 5 to 15%. In the case of iron de-
ficiency, a significant increase in iron bioavailability up to
35% can be observed [94]. Furthermore, iron uptake in the
intestinal tract is influenced by different nutritional factors
including enhancers and inhibitors. Substances enhancing
iron uptake are vitamin C, peptides from partially digested
muscle tissue, fermented food, organic acids such as malate
or citrate. Substances inhibiting iron uptake are phytates,
oxalates, polyphenols (black tea and coffee), peptides from
partially digested vegetable proteins and calcium [83, 84].
The nutritional intake should be 14 mg per day. General re-
commendations for an optimal dietary iron intake in sports
include an adequate energy intake, especially for athletes
with low body mass index as they suffer more frequently
from iron deficiency [95]. Whether catabolism related to
low energy intake influences the hepcidin regulation and
down-regulates iron uptake remains open to debate. In gen-
eral, regular consumption of meat, poultry or fish, at least
5 times per week is recommended as it is the main con-
tributor of nutritional iron intake. Complementary eating
of wholemeal products and daily legumes and green veget-
ables is suggested. Furthermore, it is beneficial to replace
tea and coffee by a glass of orange or citrus fruit juice with
an iron containing meal as vitamin C enhances iron uptake
[84, 94]. For vegetarians the goal is to reach a high load
of iron through their vegetable diet. Even if nutrition is im-
portant in iron homeostasis in the human organism, IDA
cannot be corrected by nutrition alone, as this would mean
eating kilograms of iron containing products (e.g. liver).
Oral iron
Usually dietary counselling and oral iron therapy are com-
bined. Oral preparations differ in the amount and type of
iron (Fe2+ or Fe3+), their complex forming substrate and in
their galenical form. Novel products combine iron with vit-
amin C. In a dose-finding study in elderly patients with
IDA, Rimon et al compared three doses of oral iron: 15 mg,
50 mg and 150 mg. They were able to show that iron sup-
plementation at a level of the recommended daily allow-
ances (RDA, 15 mg of elemental iron) already led to signi-
ficant increases of the iron status. In these anaemic elderly
patients, the doses of 50 mg and 150 mg of elemental iron
did not show further benefit, but had significantly more
side effects particularly in the highest dose group [96]. As
there is further evidence that oral iron loading increases
circulating hepcidin [97], the recommended dosage of oral
iron should not be too high. In a recent comparison of oral
iron supplementation in a randomised controlled trial look-
ing at iron status and performance in active women, 100
mg of FeSO4 (approximately 20 mg of elemental iron) was
shown to be effective [98]. We therefore recommend sup-
plementation of 40 to 60 mg of elemental iron once daily.
Oral iron is in general well tolerated and efficient [99].
Side effects of oral therapy are usually not serious and in-
clude nausea, dyspepsia, constipation or diarrhoea [83, 84,
100]. Some individuals with an existing tendency to con-
stipation benefit from drinking additional fruit juice to pre-
vent heavy constipation. Otherwise compliance will be ser-
iously affected.
Intravenous iron
When oral therapy fails or immediate restoration is needed
i.v. therapy should be considered. At the moment two dif-
ferent preparations are available in Switzerland, compris-
ing iron saccharose and ferric carboxymaltose [100]. The
dosage is dependent on the severity of the iron deficiency.
In one application usually 200 mg Fe-saccharose, 500 to
100 mg Fe-carboxymaltose can be administered.
The main advantage of i.v. therapy is the immediate correc-
tion of the iron deficiency and restoration of the empty iron
stores. Generally, compliance with i.v. iron supplements is
good. Side effects may encompass a transient disturbance
of taste, headache, dizziness, myalgia and fever, but severe
adverse reactions such as hypotonic and anaphylactoid re-
actions, tachycardia and arrhythmia, dyspnoea and bron-
chospasm may also be observed, albeit very rarely [100].
Moreover, transient and usually asymptomatic hypophos-
phataemia is frequently observed after the administration
of Fe-carboxymaltose [101].
It is still under discussion whether hypophosphataemia
may possibly be a cofactor for cardiac events [101].
Nowadays severe side effects are rare. For Fe-saccharose
and Fe-carboxymaltose there has been no fatal outcome re-
ported in Switzerland. This is in contrast to the previously
used iron-dextran products, which had a much higher rate
of severe and fatal side effects. In 2013, another type of i.v.
iron, Fe-oxytol, was withdrawn owing to severe hypersens-
itivity reactions in four patients, including one fatal out-
come, observed 9 months after approval by the regulatory
authorities in Switzerland [102, 103]. Even with the use of
the new preparations, severe adverse reactions cannot be
excluded, and the administration of i.v. iron preparations is
only recommended in settings where resuscitation skills are
available and observation of the patient for 30 minutes after
the end of the i.v. administration can be guaranteed [104,
105].
In general, the frequency of side effects seems to be lower
when the i.v. iron is applied by infusion instead of slow
bolus injection. Importantly, the exact dilution given by the
manufacturer needs to be respected. Further, the physician
needs to respect the WADA antidoping regulations con-
cerning administration of infusion in elite sports: “Intra-
venous infusions and/or injections of more than 50 ml per
6 hour period are prohibited except for those legitimately
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received in the course of hospital admissions or clinical in-
vestigations” [106].
Check of adequate iron stores
In sports a regular check of blood parameters is necessary,
especially in endurance athletes. To monitor efficacy of
therapeutic measures we recommend repeating the basic
blood tests 6 to 8 weeks after the start of the nutritional
measures, oral therapy or i.v. iron administration.
Depending on the blood results, therapy will be continued
or modified with the aim of reaching or to keeping the iron
stores in the regular range. Treatment approaches may be
combined and athletes with repeatedly low iron stores may
benefit from intermittent oral substitution to preserve iron
stores, e.g. substitution with 14 to 28 m elemental iron per
day or 40–60 mg elemental iron two to three times per
week. In vegetarian athletes a similar approach to prevent-
ing iron deficiency is recommended: 40 to 60 mg elemental
iron three times per week instead of meat intake or a daily
supplementation with at least 14 or 28 mg/day of iron will
usually cover iron demand.
As iron homeostasis is exclusively and meticulously con-
trolled by the iron uptake through the intestinal tract [107]
and as there is no pathway to eliminate iron in cases of
overload, iron supplementation has to be done always care-
fully. In extreme cases, chronic iron overload may lead to
secondary haemochromatosis. Furthermore, excessive sup-
plementation of oral or i.v. iron is thought to increase oxid-
ative stress and production of free radicals [108, 109] and
oxidative stress is suggested to play a role in cancer genesis
[110, 111]. This must be critically appraised as acute exer-
cise leads to oxidative stress [112, 113].
It has been shown in mice that oral iron supplementation
enhances colonic tumour development [114]. Data in hu-
mans suggest that iron may increase the risk for colorectal
cancer [115]. A recent meta-analysis showed on the one
hand a tendency toward a positive association between
high intake of haem iron and cancer risk. On the other
hand high levels of biomarkers of iron stores implied a
lower cancer risk [116]. Further prospective and experi-
mental studies are needed to evaluate the possible influence
of iron in carcinogenesis.
Iron deficiency in the child and
adolescent athlete
A British study reported an iron deficiency prevalence of
21% in adolescents between 11–18 years [117, 118]. Al-
though likely to be higher in the athletic population, data
about young athletes concerning iron deficiency are sparse
[119–121].
Total iron requirements in children and adolescents are dis-
tinctly increased because of additional iron needs for the
expansion of the total blood volume and mean haemo-
globin mass, as well as for the enhancement in lean body
mass during growth [122]. In adolescent females the onset
of menarche is associated with an increase of iron require-
ment. The mean total iron requirement for adolescents
reaches 1.8 mg/d for boys and 2.2 mg/d for girls (in females
with heavy periods it is considerably more), which corres-
ponds to more than double that in the preadolescent peri-
od [123, 124]. Otherwise risk factors for iron deficiency,
both in younger and older athletes, are the same [20, 23, 24,
125].
Haematological normal values in children and adolescents
are different from adults and should always be considered
(see table 3). We recommend defining the lower level of
normal for ferritin as 15 mcg/l for children between 6–12
years, 20 mcg/l between 12–15 years and 30 mcg/l for
15–18 year old adolescents [126].
As in adults, in a case of NAID dietary counselling is the
first step, often combined with oral therapy. Iron require-
ments (RDA) are 8 mg/d for 9–13 year-old children and 11
mg/d for male and 15 mg/d for female adolescents older
than 13 years. Careful management, especially of the men-
struating teenage girl and the vegetarian athlete, is warran-
ted [127]. If iron deficiency results in IDMH or IDA, fur-
ther supplementation should be considered. Comparable to
the therapy in adults, oral substitution can be with either
Table 3: Critical cut-offs for differentiation of iron deficiency in children and adolescents. Adapted from Herklotz et al. [29].
Definition Haemoglobin MCV/MCH Ferritin CRP
NAID Normal Normal
6–12y:
MCV <76 fl or no
MCH <25 pg or no
6–12y: <15 mcg/l
12–15 y:
MCV <78 fl or no
MCH <26 pg or no
12–15y: <20 mcg/l
IDMH Normal
15–18 y:
MCV <79 fl or no
MCH <26.5 pg or no
15–18y: <30 mcg/l
6–12 y:
<112 g/l
6–12y:
MCV <76 fl
MCH <25 pg
12–15y:
M <125 g/l
F <120 g/l
12–15y:
MCV <78 fl or no
MCH <26 pg or no
IDA
15–18y:
M <130 g/l
F <120 g/l
15–18 y:
MCV <79 fl or no
MCH <26.5 pg or no
Normal
CRP = C-reactive protein; IDA = iron deficiency anaemia; IDMH = iron deficiency with microcytosis and/or hypochromia; MCV = mean cellular
haemoglobin; MCH = mean corpuscular haemoglobin; NAID = nonanaemic iron deficiency
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Fe2+ or Fe3+ preparations. The dosage for iron preparations
is 5 mg/kg/d for 3 months in two or three daily doses. The
Fe2+ preparation is recommended as medication of choice
because of better bioavailability. As in adult athletes, meas-
urement of haemoglobin, red cell indices, ferritin and CRP
after 6–8 weeks of treatment is necessary in order to ob-
serve responsiveness and compliance with the treatment.
Conclusions and recommendations
Iron deficiency in sports is frequent and relevant as all
stages of iron deficiency ‒ IDA, IDMH and NAID ‒ affect
physical performance.
To diagnose iron deficiency, haemoglobin, haematocrit,
MCV, MCH and ferritin are first-line parameters to assess.
For a valid interpretation of the results it is necessary to
exclude acute-phase reactions that may interfere, such as
training sessions and infectious diseases (patient history
and measurement of CRP). In unclear situations a second
measurement of the same parameters or the additional
measurement of zinc-protoporphyrin, soluble transferrin
receptor and transferrin saturation may be helpful. In high
level endurance athletes basic blood examinations should
be made two to three times a year.
Ferritin values below <15 mcg/l are very specific for empty
iron stores. Ferritin values from 15 to 30 mcg/l correspond
to low iron stores. A ferritin value of 30 mcg/l should be
taken as a reasonable cut-off for adult men and women and
older adolescents (15 years and older). For younger adoles-
cents from 12 to 15 years a cut-off of 20 mcg/l and for
children from 6 to 12 years a cut-off of 15 mcg/l is re-
commended. In adult elite sports altitude training repres-
ents a special situation with an increased need for iron. In
this case a ferritin value of 50 mcg/l prior to altitude train-
ing should be aimed for. Every case of severe iron defi-
ciency warrants an extended work up, and this is also true
in sports.
Therapy of iron deficiency in sports consists of the nutri-
tional counselling including sufficient energy intake and
5 times/week haem iron intake (meat, poultry, fish) with
the addition of legumes and green vegetables (e.g. spinach,
fennel) usually combined with oral iron supplementation.
Daily oral iron preparations in a dosage of 40 to 60 mg
of elemental iron are appropriate, as the not severe but
disturbing gastrointestinal side effects are related to iron
dosage and preparation. Consider enhancers (vitamin C)
and prevent inhibitors (coffee, black tea, phytates, calcium)
of iron uptake to increase absorption. Athletes and patients
with repeatedly low ferritin values profit from intermittent
oral substitution to preserve iron stores, e.g. two iron tab-
lets per week (containing 40 to 60 mg elemental iron) as
maintenance therapy. In cases of plausible nonresponders,
incompatibility with oral therapy, a concomitant disease
(e.g. depression) or low iron stores before an altitude train-
ing camp, i.v. iron therapy should be considered.
Long-term daily oral iron intake or i.v. supplementation in
the presence of normal or even high ferritin values is not
recommended and may be harmful.
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Figures (large format)
Figure 1
Iron compartments.
Figure 2
Hepcidin effects, adapted after Young and Zaritsky 2009 [17].
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Figure 3
Stages of iron deficiency.
Hb = haemoglobin; IDA = iron deficiency anaemia; IDMH = iron deficiency with microcytosis and/or hypochromia; MCH = mean cellular
haemoglobin; MCV = mean cellular volume; NAID = nonanaemic iron deficiency; sTfr = soluble transferrin receptor; ZnPP = zinc protoporphyrin
Figure 4
Overview of diagnosis and indications for treatment in adults.
CRP = C-reactive protein; Hb = haemoglobin; Hk = haematocrit;IDA =iron deficiency with anaemia; IDMH =iron deficiency with microcytosis and/
or hypochromia; MCH = mean cellular haemoglobin; MCV = mean cellular volume; NAID =nonanaemic iron deficiency; ; ZnPP = zinc
protoporphyrin
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Figure 5
Total blood volume of male and female untrained, top athletes and athletes with dilutional pseudoanaemia in ml [44, 46, 49].
APA = athlete with dilutional pseudoanaemia; TA = top athlete; UT = untrained
In the column of the red cell mass the haematocrit in percentage is shown in white letters.
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